Tag: Non-small cell lung cancer

Avistone Biotechnology receives NMPA approval for Vebreltinib in China

businessnewstoday- November 19, 2023

Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical Products Administration (NMPA) of China for commercializing ... Read More

AstraZeneca’s PACIFIC-2 Phase 3 trial for Imfinzi in NSCLC falls short of primary endpoint

businessnewstoday- November 14, 2023

In the latest development in oncology research, AstraZeneca's PACIFIC-2 Phase III trial, involving Imfinzi (durvalumab) concurrently administered with platinum-based chemoradiotherapy (CRT), did not achieve statistical ... Read More

Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC

businessnewstoday- November 4, 2023

Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its ... Read More

Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

businessnewstoday- September 3, 2023

Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

businessnewstoday- August 6, 2023

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

businessnewstoday- July 11, 2023

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More

Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC

Raghuram Kadari- December 28, 2022

Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination ... Read More

Biomea Fusion to take BMF-219 into clinical trials for KRAS solid tumors

businessnewstoday- October 16, 2022

Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal ... Read More

Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300

pallavi123- July 17, 2022

Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of ... Read More

BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn

pallavi123- June 14, 2022

Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More